Grundlæggende statistik
| LEI | 549300PCOT1RLQ23DL21 |
| CIK | 744452 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Applied DNA Sciences, Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| June 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2026 BNB Plus Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| May 27, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), is dated as of May 26, 2026, between BNB Plus Corp., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto or that becomes a purchaser in accordance with Section 2.1(b)(each, including its successors and assigns, a “Purchaser” and collectively, the “Purcha |
|
| May 27, 2026 |
Exhibit 10.3 GUARANTY AGREEMENT (Treasury Subsidiary Guaranty of Series B-1 and Series B-2 Convertible Preferred Stock Obligations) THIS TREASURY SUBSIDIARY GUARANTY AGREEMENT (this “Agreement”), dated as of May 26, 2026, is made by BNBX Ltd., a British Virgin Islands business corporation and Build & Build LLC, a Delaware limited liability company, both wholly-owned subsidiaries of BNB Plus Corp, |
|
| May 27, 2026 |
Exhibit 3.1 BNB Plus Corp. Certificate of Designations of Series B-1 Convertible Preferred Stock Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned hereby certifies that on May 19, 2026 the Board of Directors of BNB Plus Corp., a Delaware corporation (the “Company”), adopted the following resolution designating and creating, out of the authorized and un |
|
| May 27, 2026 |
PREFUNDED SERIES B-1 PREFERRED STOCK PURCHASE WARRANT BNB PLUS CORP. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUAN |
|
| May 27, 2026 |
SERIES F COMMON STOCK PURCHASE WARRANT BNB PLUS CORP. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUAN |
|
| May 27, 2026 |
Exhibit 3.2 BNB Plus Corp. Certificate of Designations of Series B-2 Convertible Preferred Stock Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned hereby certifies that on May 19, 2026 the Board of Directors of BNB Plus Corp., a Delaware corporation (the “Company”), adopted the following resolution designating and creating, out of the authorized and un |
|
| May 27, 2026 |
BNB PLUS CORP. 25 Health Sciences Drive Stony Brook, NY 11790 Exhibit 10.2 BNB PLUS CORP. 25 Health Sciences Drive Stony Brook, NY 11790 May 26, 2026 Holders of Series E Common Stock Purchase Warrants Re: Warrant Inducement and Exchange Agreement Dear Holder: BNB Plus Corp. (the “Company”) is pleased to offer to you (a “Holder”, “you” or similar terminology) the opportunity to receive securities of the Company pursuant to Section 4(a)(2) of th |
|
| May 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2026 BNB Plus Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Number) 59-226271 |
|
| May 27, 2026 |
BNB Plus Corp. (BNBX) Secures Initial Commitments for $4.1M in Strategic Financing Exhibit 99.1 BNB Plus Corp. (BNBX) Secures Initial Commitments for $4.1M in Strategic Financing Silvermine Capital Leads New and Existing Investor Group in Partnership with GlobalStake to Support Strategic Review of Digital Asset and Biotechnology Businesses Additional Commitments Expected with the Company Targeting $5m in Total Proceeds NEW YORK - BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the |
|
| May 27, 2026 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 26, 2026, between BNB Plus Corp., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agreement |
|
| May 27, 2026 |
PREFUNDED SERIES B-2 PREFERRED STOCK PURCHASE WARRANT Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD OR OTHERWISE TRANSFERRED EXCEPT PUR |
|
| May 27, 2026 |
Exhibit 4.4 TRANSFERABLE RIGHTS AGREEMENT This Transferable Rights Agreement (this “Agreement”) is made as of May 26, 2026 between BNB Plus Corp., a Delaware corporation (the “Company”), and the holder identified on the signature page, including its successors and assigns (the “Holder”). WHEREAS, pursuant to the terms of the Warrant Inducement and Exchange Agreement (the “Inducement Agreement”) en |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 BN |
|
| April 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 28, 2026 BNB Plus Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Number) 59-2262 |
|
| March 24, 2026 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 20, 2026 BNB Plus Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Number) 59-2262 |
|
| March 12, 2026 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| February 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 |
|
| February 5, 2026 |
Exhibit 10.1 February 2, 2026 James Haft [***] (FOR ALL NOTICES : via email [***]) Dear James: On behalf of BNB Plus Corp., a Delaware corporation (the “Company”), I am pleased to extend to you an offer to join the Company’s Board of Directors (the “Board”) as a non-employee independent director and member of the Nominating Committee effective on or about February 3, 2026. This offer is contingent |
|
| February 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 2, 2026 BNB Plus Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Number) 59-22 |
|
| February 5, 2026 |
Exhibit 99.1 BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board Director Digital Asset and Infrastructure Expert Joins Board to Support Strategic Growth and BNB Treasury Operations New York, NY – February 5, 2026 – BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced the appointment of James Haft as an Independent Director and member of the Board’s Nominating Commit |
|
| January 30, 2026 |
APPLIED DNA SCIENCES, INC. 2020 EQUITY INCENTIVE PLAN Exhibit 10.1 APPLIED DNA SCIENCES, INC. 2020 EQUITY INCENTIVE PLAN Section 1. Purpose; Definitions. The purposes of the Applied DNA Sciences, Inc. 2020 Equity Incentive Plan (as amended from time to time, the “Plan”) are to: (a) enable Applied DNA Sciences, Inc. (the “Company”) and its affiliated companies to recruit and retain highly qualified employees, directors and consultants; (b) provide tho |
|
| January 30, 2026 |
As filed with the Securities and Exchange Commission on January 30, 2026 As filed with the Securities and Exchange Commission on January 30, 2026 Registration No. |
|
| January 30, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 BNB PLUS CORP. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.001 per share Other 5,000,000 $ 1.55 $ 7,750,000.00 0.0001381 $ 1,070.27 Total Offering Amo |
|
| January 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 15, 2026 BNB Plus Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Number) 59-22 |
|
| December 30, 2025 |
BNB Plus Corp. Up to 18,728,341 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-291156 PROSPECTUS BNB Plus Corp. Up to 18,728,341 Shares of Common Stock This prospectus relates to the resale from time to time by the selling stockholders (the “Selling Stockholders”) identified in this prospectus under the caption “Selling Stockholders” of up to an aggregate of 18,728,341 shares (the “Shares”) of common stock, par |
|
| December 22, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36745 BNB PLUS C |
|
| December 22, 2025 |
As filed with the Securities and Exchange Commission on December 22, 2025. As filed with the Securities and Exchange Commission on December 22, 2025. Registration Statement No. 333-291156 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BNB Plus Corp. (Exact name of registrant as specified in its charter) Delaware 7380 59-2262718 (State or other jurisdiction of inco |
|
| December 22, 2025 |
SUBSIDIARIES OF BNB PLUS CORP. Exhibit 21.1 SUBSIDIARIES OF BNB PLUS CORP. Subsidiary State or Country of Incorporation APDN (B.V.I.) Inc. British Virgin Islands Applied DNA Sciences Europe Limited United Kingdom Applied DNA Sciences India Private Limited India LineaRX, Inc. Delaware Applied DNA Clinical Labs LLC Delaware Spindle Biotech, Inc. Canada Build & Build LLC Delaware BNBX Ltd. British Virgin Islands |
|
| December 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 12, 2025 BNB Plus Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Number) 59-2 |
|
| November 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 13, 2025 BNB Plus Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-36745 (Commission F |
|
| November 17, 2025 |
CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF APPLIED DNA SCIENCES, INC. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF APPLIED DNA SCIENCES, INC. Applied DNA Sciences, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), DOES HEREBY CERTIFY: FIRST: The first sentence of Article I of the Certificate of Incorporation, as amended (the “Certificate of Incorporation” |
|
| November 17, 2025 |
Exhibit 99.1 Applied DNA Rebrands as BNB Plus Corp., Elects Josh Kruger as Chairman of the Board Rebrand Aligned with Yield-Focused BNB Treasury and BNBX Ticker Appointment Strengthens DeFi Leadership STONY BROOK, N.Y. – November 17, 2025 – Applied DNA Sciences, Inc. (NASDAQ: BNBX) (the “Company”) today announced that it will change its name to BNB Plus Corp. (“BNB Plus”), reflecting the Company's |
|
| November 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the registrant x Filed by a party other than the registrant o Check the appropriate box: Preliminary Proxy Statement o Confidential for Use of the Commission only (as permitted by Rule 14a-6(e)(2) o Definitiv |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-36745 (C |
|
| November 10, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| November 4, 2025 |
AT THE MARKET OFFERING AGREEMENT Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT November 4, 2025 Lucid Capital Markets, LLC 570 Lexington Avenue, 40th Floor New York, New York 10022 Ladies and Gentlemen: Applied DNA Sciences, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with Lucid Capital Markets, LLC (the “Manager”) as follows: 1. Definitions. The |
|
| November 4, 2025 |
APPLIED DNA SCIENCES, INC. Up to $8,157,932 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-272267 PROSPECTUS SUPPLEMENT (To prospectus dated June 6, 2023) APPLIED DNA SCIENCES, INC. Up to $8,157,932 Common Stock We have entered into an At The Market Offering Agreement (the “Sales Agreement”), with Lucid Capital Markets, LLC (“Lucid”), relating to shares of our common stock offered by this prospectus supplement and the accompanying pr |
|
| November 4, 2025 |
Exhibit 99.1 CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is entered into as of October 1, 2025 (the “Effective Date”) by and between Applied DNA Sciences, Inc. a Delaware corporation located at 50 Health Sciences Drive, Stony Brook, New York, 11790 (the “Company”) and Patrick Horsman, with an address of [] (“Consultant”). The Company desires to retain Consultant as an independent |
|
| November 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation ) 001-36745 (Commission File |
|
| October 30, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| October 30, 2025 |
As filed with the Securities and Exchange Commission on October 29, 2025. Table of Contents As filed with the Securities and Exchange Commission on October 29, 2025. |
|
| October 30, 2025 |
Calculation of Filing Fee Tables S-1 APPLIED DNA SCIENCES INC Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0. |
|
| October 23, 2025 |
Exhibit 99.1 Applied DNA Sciences Closes up to $58 Million Private Placement; Announces Initial BNB Holdings Valued at Over $17 Million Company Officially Launches Yield-Focused Digital Asset Treasury Strategy Streamlines Operations, Achieving Approximately $2.9 Million in Annualized Cost Savings STONY BROOK, N.Y. – October 22, 2025 - Applied DNA Sciences, Inc. (NASDAQ: BNBX) (“Applied DNA”, “BNBX |
|
| October 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 21, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-36745 (C |
|
| October 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| October 6, 2025 |
Ticker changing from 'APDN' to 'BNBX' effective October 7, 2025 Exhibit 99.1 Applied DNA Sciences to Begin Trading Under New Ticker 'BNBX' Reflecting Digital Asset Treasury Strategy Ticker changing from 'APDN' to 'BNBX' effective October 7, 2025 STONY BROOK, N.Y. - Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a biotechnology company advancing a yield focused BNB digital asset treasury strategy and commercializing nucleic acid pro |
|
| October 1, 2025 |
SERIES E-1 COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Exhibit 4.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 1, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), including the Summary of Recent Developments set forth in Annex A and the Risk Factors set forth in Annex B, is dated as of September , 2025, between Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its suc |
|
| October 1, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT applied dna sciences, inc. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 1, 2025 |
Summary of Recent Developments Exhibit 99.2 Summary of Recent Developments Private Placement Offering On September 29, 2025, Applied DNA Sciences, Inc., a Delaware corporation (the “Company”) entered into a securities purchase agreement (the “Cash Securities Purchase Agreement”) with certain accredited investors (the “Cash Purchasers”) pursuant to which the Company agreed to sell and issue to the Cash Purchasers in a private pl |
|
| October 1, 2025 |
STRATEGIC DIGITAL ASSETS SERVICES AGREEMENT Exhibit 10.5 STRATEGIC DIGITAL ASSETS SERVICES AGREEMENT This STRATEGIC DIGITAL ASSETS SERVICES AGREEMENT (this “Agreement”), by and between Applied DNA Sciences, Inc., a Delaware corporation with its principal place of business at 50 Health Sciences Drive, Stony Brook, NY 11790 (“Client”), and Cypress LLC, a Puerto Rico limited liability company with its principal place of business at 2067 Calle |
|
| October 1, 2025 |
Exhibit 10.6 STRATEGIC ADVISOR AGREEMENT This STRATEGIC ADVISOR AGREEMENT (this “Agreement”) by and between Applied DNA Sciences, Inc., a Delaware corporation with its principal place of business at 50 Health Sciences Drive Stony Brook, NY 11790 (“Customer”), and Cypress Management LLC, a Puerto Rico limited liability company with its principal place of business at 2067 Calle Espana #4 San Juan, P |
|
| October 1, 2025 |
SERIES E-1 COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Exhibit 4.6 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 1, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| October 1, 2025 |
Executive Employment Agreement Exhibit 10.8 Executive Employment Agreement This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of September 29th, 2025 (the “Effective Date”), by and between Applied DNA Sciences, Inc. a Delaware corporation (together with its successors and assigns, the “Company”), and Clay Shorrock (“Executive”). RECITALS WHEREAS, the Company desires to employ Executive as its Chief Executive Offi |
|
| October 1, 2025 |
SERIES E-1 COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 1, 2025 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of September , 2025, between Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Pu |
|
| October 1, 2025 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of September , 2025, between Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Pu |
|
| October 1, 2025 |
Executive Officer Transition and Separation Agreement Exhibit 10.7 Executive Officer Transition and Separation Agreement THIS EXECUTIVE OFFICER transition and SEPARATION AGREEMENT (the “Separation Agreement”) is made and entered into and is effective as of this 29th day of September, 2025 (the “Effective Date”) by and between Applied DNA Sciences, Inc. (herein the “Employer” or “Company”) and Judith Murrah (herein “Employee”) and for good and valuabl |
|
| October 1, 2025 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), including the Summary of Recent Developments set forth in Annex A and the Risk Factors set forth in Annex B, is dated as of September , 2025, between Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its suc |
|
| October 1, 2025 |
Exhibit 99.1 Applied DNA Sciences Announces Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation Appoints TradFi and DeFi Leaders as Advisers, Including Anthony Scaramucci Enhanced Staking and Yield Strategy Focused on BNB Native Yield Integrating DeFi and Binance Ecosystem Expertise Offering Led by Institutional and Crypto-Native Investors inclu |
|
| October 1, 2025 |
SERIES E-2 COMMON STOCK PURCHASE WARRANT Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| October 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 29, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-36745 |
|
| October 1, 2025 |
Exhibit 99.3 Risk Factors1 Risks Related to Cryptocurrencies The further development and acceptance of the BNB chain (the “BNB Chain”) and other cryptocurrency networks, which represent a relatively new and rapidly changing industry, are subject to a variety of factors that are difficult to evaluate. The slowing or stopping of the development or acceptance of the BNB Chain and other cryptocurrency |
|
| October 1, 2025 |
Executive Employment Agreement Exhibit 10.9 Executive Employment Agreement This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of September 29th, 2025 (the “Effective Date”), by and between Applied DNA Sciences, Inc. a Delaware corporation (together with its successors and assigns, the “Company”), and Beth Jantzen (“Executive”). RECITALS WHEREAS, the Company desires to employ Executive as its Chief Executive Offic |
|
| September 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 29, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-36745 |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Nu |
|
| August 14, 2025 |
Applied DNA Reports Third Quarter Fiscal 2025 Financial Results Exhibit 99.1 Applied DNA Reports Third Quarter Fiscal 2025 Financial Results STONY BROOK, N.Y. – August 14, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a biotechnology company focused on providing nucleic acid production solutions for the biopharmaceutical and diagnostics industries, today reported financial results for its third quarter of fiscal 2025 ended |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 App |
|
| July 25, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Applied DNA Sciences, Inc. |
|
| July 25, 2025 |
As filed with the Securities and Exchange Commission on July 24, 2025 As filed with the Securities and Exchange Commission on July 24, 2025 Registration No. |
|
| July 25, 2025 |
Exhibit 3.1 CERTIFICATE OF INCORPORATION OF APPLIED DNA SCIENCES, INC. a Delaware corporation The undersigned, for the purpose of forming a corporation pursuant to the provisions of the General Corporation Law of the State of Delaware, does hereby certify as follows: ARTICLE I The name of this corporation is Applied DNA Sciences, Inc. ARTICLE II The address of its registered office in the State of |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numbe |
|
| June 30, 2025 |
Exhibit 99.1 Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx - Conducts 27% Workforce Reduction, Ceases Operations at Applied DNA Clinical Labs, Positions LineaRx for Growth - STONY BROOK, N.Y. – June 30, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN), a leader in PCR-based DNA technologies, announced a |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numb |
|
| June 17, 2025 |
Exhibit 99.1 Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward - President and COO Judy Murrah Appointed New Chairperson of the Board of Directors and CEO - STONY BROOK, N.Y. – June 17, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced that Chairperson and Chief Executive Officer Dr. |
|
| June 17, 2025 |
Exhibit 10.1 Executive Officer Separation Agreement THIS EXECUTIVE OFFICER SEPARATION AGREEMENT (the “Separation Agreement”) is made and entered into and is effective as of this 16th day of June, 2025 (the “Effective Date”) by and between Applied DNA Sciences, Inc. (herein the “Employer” or “Company”) and Dr. James A. Hayward (herein “Employee”) and for good and valuable consideration including th |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numb |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 30, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numbe |
|
| May 29, 2025 |
Form of Eighth Certificate of Amendment to the Certificate of Incorporation. Exhibit 3.1 PROPOSED FORM OF CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF APPLIED DNA SCIENCES, INC. Applied DNA Sciences, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY THAT: FIRST: Article IV of the Certificate of Incorporation, as amended (the “Certificate of Incorporation”), of th |
|
| May 29, 2025 |
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025 Exhibit 99.1 Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025 STONY BROOK, N.Y. – May 29, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12 |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 29, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numbe |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 22, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numbe |
|
| May 15, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numbe |
|
| May 15, 2025 |
Exhibit 99.1 Applied DNA Reports Second Quarter Fiscal 2025 Financial Results - Therapeutic DNA Production Services Segment (LineaRx) Revenues Up 44% Y/Y, Contributing to a 6% Increase in Total Revenues - - Intra-Quarter Investor Conference Call and Webcast Scheduled for June 3, 2025, at 4:30 PM ET - STONY BROOK, N.Y. – May 15, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 Ap |
|
| April 15, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 7, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numb |
|
| April 4, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Num |
|
| March 12, 2025 |
Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025 Exhibit 99.1 Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025 STONY BROOK, N.Y. – March 12, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-50 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 12, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Num |
|
| March 12, 2025 |
Form of Seventh Certificate of Amendment to the Certificate of Incorporation Exhibit 3.1 SEVENTH CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF APPLIED DNA SCIENCES, INC. Applied DNA Sciences, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY THAT: FIRST: Article IV of the Certificate of Incorporation, as amended (the “Certificate of Incorporation”), of the Corpora |
|
| February 28, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| February 14, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 14, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| February 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| February 13, 2025 |
Exhibit 99.1 Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress - Announces Exit of DNA Tagging and Security Products and Services Business Segment - - Workforce Reduction of 20% of Headcount Implemented in January - - GMP Site 1 Facility Complete and Certified for Commercial Operation in January - - Webcast and Conference Call Scheduled for today a |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ |
|
| January 30, 2025 |
Letter from Marcum dated January 30, 2025 Exhibit 16.1 January 30, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Applied DNA Sciences, Inc. under Item 4.01 of its Form 8-K dated January 30, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Applied DNA Sciences, I |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 24, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| January 23, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 23, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| January 17, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-283315 PROSPECTUS Up to 20,312,500 shares of Common Stock underlying the Series C Warrants Up to 20,312,500 shares of Common Stock underlying the Series D Warrants Up to 1,015,625 shares of Common Stock underlying the Placement Agent Warrants Applied DNA Sciences, Inc. This prospectus relates to the resale from time to time, by the se |
|
| January 15, 2025 |
Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 January 15, 2025 Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 January 15, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Re: Applied DNA Sciences, Inc. Registration Statement on Form S-1 Filed November 19, 2024, as amended File No. 333-283315 Ladies and Gentlemen: Pursuant to Rule 461 under the Secu |
|
| January 13, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| January 13, 2025 |
Exhibit 99.1 ©2025 Applied DNA Sciences, Inc. Empowering the Genetic Medicines Revolution Nasdaq: APDN January 2025 ©2025 Applied DNA Sciences, Inc. 2 The statements made by Applied DNA in this presentation may be “forward - looking” in nature within the meaning of Section 27 A of the Securities Act of 1933 , Section 21 E of the Securities Exchange Act of 1934 and the Private Securities Litigation |
|
| January 10, 2025 |
As filed with the Securities and Exchange Commission on January 10, 2025. As filed with the Securities and Exchange Commission on January 10, 2025. Registration Statement No. 333-283315 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Applied DNA Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 7380 59-2262718 (State or other jurisdict |
|
| December 17, 2024 |
Exhibit 19.1 APPLIED DNA INSIDER TRADING POLICY Purpose The purpose of this Insider Trading Policy is to define those individuals who are designated as “insiders” for the purpose of APDN stock trading restrictions and to outline the obligations of insiders regarding insider trading and federal securities laws. Except where otherwise explicitly stated, this insider trading policy applies to all emp |
|
| December 17, 2024 |
Subsidiaries of Applied DNA Sciences, Inc. Exhibit 21.1 SUBSIDIARIES OF APPLIED DNA SCIENCES, INC. Subsidiary State or Country of Incorporation APDN (B.V.I.) Inc. British Virgin Islands Applied DNA Sciences Europe Limited United Kingdom Applied DNA Sciences India Private Limited India LineaRX, Inc. Delaware Applied DNA Clinical Labs LLC Delaware Spindle Biotech, Inc. Canada |
|
| December 17, 2024 |
Exhibit 97.1 Applied DNA Sciences, Inc. (the “Company”) Compensation Clawback Policy Effective Date: October 2, 2023 1. Purpose. The Company has adopted this Policy to comply with Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as codified by Section 10D of the Exchange Act, and Nasdaq Listing Rule 5608, which require the recovery of certain forms of executive |
|
| December 17, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36745 APPLIED DN |
|
| December 17, 2024 |
Exhibit 99.1 Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines - Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership - - Buildout of GMP Manufacturing Facility to be Completed by January 9, 2025 - - Webcast and Conference |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 17, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| November 26, 2024 |
November 26, 2024 James Hayward Chief Executive Officer Applied DNA Sciences, Inc. |
|
| November 19, 2024 |
As filed with the Securities and Exchange Commission on November 18, 2024. As filed with the Securities and Exchange Commission on November 18, 2024. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Applied DNA Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 7380 59-2262718 (State or other jurisdiction of incorporat |
|
| November 19, 2024 |
Exhibit 3.2 BYLAWS OF APPLIED DNA SCIENCES, INC. TABLE OF CONTENTS Page ARTICLE I CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 NOTICE OF STOCKHOLDERS’ MEETINGS 2 2.5 MANNER OF GIVING NOTICE; AFFIDAVIT OF NOTICE 3 2.6 QUORUM 3 2.7 ADJOURNED MEETING; NOTICE 3 2.8 ADMINISTRA |
|
| November 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) APPLIED DNA SCIENCES, INC. |
|
| November 14, 2024 |
EX-99.1 2 d834912dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value, of Applied DNA Sciences, Inc., a Delaware corp |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| November 14, 2024 |
APDN / Applied DNA Sciences, Inc. / Anson Funds Management LP - SC 13G Passive Investment SC 13G 1 d834912dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) (Amendment No.) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) APPLIED DNA SCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 03815U409 (CUSIP N |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 12, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| November 13, 2024 |
APDN / Applied DNA Sciences, Inc. / Grossman Bruce - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 eh24055609513ga1-adna.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied DNA Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03815U201 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the app |
|
| November 7, 2024 |
APDN / Applied DNA Sciences, Inc. / Leviticus Partners LP Passive Investment SC 13G/A 1 apdn13gNEWa1.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1)* Applied DNA Sciences, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 03815U409 - (CUSIP Number) 10/30/2024 - (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| November 7, 2024 |
Certificate of Amendment to the Bylaws Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE BYLAWS OF APPLIED DNA SCIENCES, INC. FIRST: The Bylaws (“Bylaws”) of Applied DNA Sciences, Inc., a Delaware corporation (the “Corporation”) have been amended as follows: Section 2.6 of Article II of the Bylaws shall be amended and restated in its entirety to state as follows: “2.6 QUORUM. The holders of one-third of the stock issued and outstanding and e |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| October 31, 2024 |
Form of Series C Common Stock Purchase Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 31, 2024 |
Form of Placement Agent Warrant Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 31, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-272267 PROSPECTUS SUPPLEMENT (To prospectus dated June 6, 2023) APPLIED DNA SCIENCES, INC. 19,247,498 Shares of Common Stock Pre-Funded Warrants to Purchase 1,065,002 Shares of Common Stock We are offering 19,247,498 shares of our common stock (the “Shares”) at a price of $0.32 per share to investors (the “Purchasers”) pursuant to this prospect |
|
| October 31, 2024 |
Exhibit 99.1 Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement STONY BROOK, N.Y., - October 30, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced the pricing of a registered direct offering and concurrent private placement with gross proceeds to the Compa |
|
| October 31, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 30, 2024, between Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| October 31, 2024 |
Exhibit 10.2 AMENDMENT TO SERIES A COMMON STOCK PURCHASE WARRANT THIS AMENDMENT TO SERIES A COMMON STOCK PURCHASE WARRANT (this “Amendment”), dated as of October 29, 2024, is by and between Applied DNA Sciences, Inc., a Delaware corporation (the "Company"), and the undersigned holder (the “Holder”). WHEREAS, pursuant to a Placement Agency Agreement, dated May 28, 2024, by and among the Company, Cr |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| October 31, 2024 |
Exhibit 10.3 WAIVER OF SUBSEQUENT EQUITY SALES PROVISION October 29, 2024 Reference is hereby made to Section 4(p) of that certain Placement Agency Agreement (the “Placement Agency Agreement”), dated May 28, 2024, by and among Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), Craig-Hallum Capital Group LLC (“Craig-Hallum”) and Laidlaw & Company (UK) Ltd. Capitalized terms used bu |
|
| October 31, 2024 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Initial Exercise Date: [], 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t |
|
| October 31, 2024 |
Form of Series D Common Stock Purchase Warrant Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 2, 2024 |
APDN / Applied DNA Sciences, Inc. / Leviticus Partners LP Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. )* Applied DNA Sciences, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 03815U409 - (CUSIP Number) 10/01/2024 - (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this schedule i |
|
| September 30, 2024 |
Exhibit 107 FEE TABLES FOR FORM S-8 Calculation of Filing Fee Tables Form S-8 (Form Type) Applied DNA Sciences, Inc. |
|
| September 30, 2024 |
As filed with the Securities and Exchange Commission on September 30, 2024 As filed with the Securities and Exchange Commission on September 30, 2024 Registration No. |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 17, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| September 18, 2024 |
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement STONY BROOK, N.Y., - September 18, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on September 17, 2024, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market |
|
| August 21, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| August 19, 2024 |
APDN / Applied DNA Sciences, Inc. / Leviticus Partners LP Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (AMENDMENT NO. 4)* Applied DNA Sciences, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 03815U409 - (CUSIP Number) 08/19/2024 - (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this schedul |
|
| August 9, 2024 |
APDN / Applied DNA Sciences, Inc. / Leviticus Partners LP Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (AMENDMENT NO. 3)* Applied DNA Sciences, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 03815U409 - (CUSIP Number) 08/08/2024 - (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this schedul |
|
| August 8, 2024 |
Exhibit 99.1 Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results - Conference Call/Webcast Scheduled for Today at 4:30 PM ET - STONY BROOK, N.Y. – August 8, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for its third fiscal quarter ended June 30, 2024. The |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Num |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 App |
|
| August 5, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| August 2, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 2, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Num |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 12, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numb |
|
| June 28, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numb |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| June 24, 2024 |
APDN / Applied DNA Sciences, Inc. / Leviticus Partners LP Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2)* Applied DNA Sciences, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 03815U409 - (CUSIP Number) 06/20/2024 - (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this schedul |
|
| June 21, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| June 18, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 18, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numb |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| June 7, 2024 |
SC 13G 1 l1cap13g.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Applied DNA Sciences Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03815U409 (CUSIP Number) May 28, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| June 7, 2024 |
SC 13G 1 shn13g.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Applied DNA Sciences Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03815U409 (CUSIP Number) May 28, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| June 3, 2024 |
APPDW / Applied DNA Sciences, Inc. - Equity Warrant / Leviticus Partners LP Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1)* Applied DNA Sciences, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 03815U409 - (CUSIP Number) 05/28/2024 - (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this schedul |
|
| May 29, 2024 |
Exhibit 4.2 SERIES A COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Issuance Date: [], 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockhold |
|
| May 29, 2024 |
Exhibit 4.4 PREFUNDED COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Initial Exercise Date: [], 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| May 29, 2024 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT May 28, 2024 Craig-Hallum Capital Group LLC 222 South Ninth Street, Suite 350 Minneapolis, Minnesota 55402 Laidlaw & Company (UK) Ltd. 521 Fifth Avenue, 12th Floor New York, NY 10175 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), hereby agr |
|
| May 29, 2024 |
Applied DNA Announces Pricing of $12 Million Public Offering Exhibit 99.1 Applied DNA Announces Pricing of $12 Million Public Offering STONY BROOK, N.Y., - May 28, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced the pricing of a public offering with gross proceeds to the Company expected to be approximately $12.0 million, before deducting placement agent fees and othe |
|
| May 29, 2024 |
Form of Placement Agent Warrant Exhibit 4.1 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Initial Exercise Date: [], 2024 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| May 29, 2024 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-278890 Applied DNA Sciences, Inc. Up to 9,230,769 Units, Each Unit Consisting of One Share of Common Stock or One Pre-Funded Warrant to Purchase One Share of Common Stock, One Series A Warrant to Purchase One Share of Common Stock and One Series B Warrant to Purchase One Share of Common Stock Placement Agent Warrants to Purchase Up to 461,538 S |
|
| May 29, 2024 |
Exhibit 4.3 SERIES B COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Issuance Date: [], 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 28, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorporation) (Commission |
|
| May 24, 2024 |
As filed with the Securities and Exchange Commission on May 24, 2024 As filed with the Securities and Exchange Commission on May 24, 2024 Registration No. |
|
| May 24, 2024 |
Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 May 24, 2024 Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 May 24, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-3720 Re: Applied DNA Sciences, Inc. Registration Statement on Form S-1 Filed April 24, 2024, as amended File No. 333-278890 Ladies and Gentle |
|
| May 24, 2024 |
Exhibit 4.15 SERIES A COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Issuance Date: [], 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockhol |
|
| May 24, 2024 |
Exhibit 4.16 SERIES B COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Issuance Date: [], 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockhol |
|
| May 24, 2024 |
Exhibit 107 Registrant Name in English, if applicable (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Fee Calculation Proposed Maximum or Carry Maximum Aggregate Amount of Security Security Forward Amount Offering Offering Registration Type Class Title Rule Registered Price Price(1) Fee Rate Fee (2) Fees to be Paid Equity Units, each consisting of: (i) one share of common stock, $0. |
|
| May 22, 2024 |
Exhibit 4.15 SERIES A COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Issuance Date: [], 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| May 22, 2024 |
Form of Placement Agency Agreement Exhibit 10.50 PLACEMENT AGENCY AGREEMENT [], 2024 Craig-Hallum Capital Group LLC 222 South Ninth Street, Suite 350 Minneapolis, Minnesota 55402 Laidlaw & Company (UK) Ltd. 521 Fifth Avenue, 12th Floor New York, NY 10175 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), hereby agrees |
|
| May 22, 2024 |
Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 May 22, 2024 Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 May 22, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-3720 Re: Applied DNA Sciences, Inc. Registration Statement on Form S-1 Filed April 24, 2024, as amended File No. 333-278890 Ladies and Gentle |
|
| May 22, 2024 |
Exhibit 4.16 SERIES B COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Issuance Date: [], 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| May 22, 2024 |
As filed with the Securities and Exchange Commission on May 22, 2024 As filed with the Securities and Exchange Commission on May 22, 2024 Registration No. |
|
| May 21, 2024 |
Exhibit 107 Registrant Name in English, if applicable (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Fee Calculation Proposed Maximum or Carry Maximum Aggregate Amount of Security Security Forward Amount Offering Offering Registration Type Class Title Rule Registered Price Price(1) Fee Rate Fee (2) Fees Previously Paid Equity Units, each consisting of: (i) one share of common stock, $0. |
|
| May 21, 2024 |
Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 May 21, 2024 Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 May 21, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-3720 Re: Applied DNA Sciences, Inc. Registration Statement on Form S-1 Filed April 24, 2024, as amended File No. 333-278890 Ladies and Gentle |
|
| May 21, 2024 |
As filed with the Securities and Exchange Commission on May 21, 2024 As filed with the Securities and Exchange Commission on May 21, 2024 Registration No. |
|
| May 21, 2024 |
Exhibit 4.16 SERIES B COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Issuance Date: [], 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| May 21, 2024 |
Exhibit 4.15 SERIES A COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Issuance Date: [], 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorporation) (Commission |
|
| May 16, 2024 |
Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 May 16, 2024 Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 May 16, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-3720 Re: Applied DNA Sciences, Inc. Registration Statement on Form S-1 Filed April 24, 2024, as amended File No. 333-278890 Ladies and Gentle |
|
| May 15, 2024 |
Form of Placement Agency Agreement Exhibit 10.50 PLACEMENT AGENCY AGREEMENT [], 2024 Craig-Hallum Capital Group LLC 222 South Ninth Street, Suite 350 Minneapolis, Minnesota 55402 Laidlaw & Company (UK) Ltd. 521 Fifth Avenue, 12th Floor New York, NY 10175 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), hereby agrees |
|
| May 15, 2024 |
Exhibit 4.15 SERIES A COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Initial Exercise Date: [], 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| May 15, 2024 |
As filed with the Securities and Exchange Commission on May 14, 2024 As filed with the Securities and Exchange Commission on May 14, 2024 Registration No. |
|
| May 15, 2024 |
Exhibit 3.1 CERTIFICATE OF INCORPORATION OF APPLIED DNA SCIENCES, INC. a Delaware corporation The undersigned, for the purpose of forming a corporation pursuant to the provisions of the General Corporation Law of the State of Delaware, does hereby certify as follows: ARTICLE I The name of this corporation is Applied DNA Sciences, Inc. ARTICLE II The address of its registered office in the State of |
|
| May 15, 2024 |
Exhibit 10.51 LOCK-UP AGREEMENT [], 2024 Craig-Hallum Capital Group LLC, acting as placement agent of the Offering (as defined below): Re: Offering (as defined below) by Applied DNA Sciences, Inc. (the “Company”) Ladies and Gentlemen: The undersigned irrevocably agrees with the Company that, from the date hereof until ninety (90) days following the closing of the Company’s offering of registered s |
|
| May 15, 2024 |
Form of Placement Agent Warrant Exhibit 4.17 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Initial Exercise Date: [], 2024 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| May 15, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Applied DNA Sciences, Inc. |
|
| May 15, 2024 |
Exhibit 4.14 PREFUNDED COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Initial Exercise Date: [], 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t |
|
| May 15, 2024 |
Exhibit 4.16 SERIES B COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Initial Exercise Date: [], 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorporation) (Commission |
|
| May 10, 2024 |
Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results Exhibit 99.1 Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results STONY BROOK, N.Y. – May 10, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for its second fiscal quarter ended March 31, 2024. The Company’s Form 10-Q can be viewed at https://investors.adnas. |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 Ap |
|
| May 2, 2024 |
United States securities and exchange commission logo May 2, 2024 James Hayward Chairman, Chief Executive Officer and President APPLIED DNA SCIENCES INC 50 Health Sciences Drive Stony Brook, New York 11790 Re: APPLIED DNA SCIENCES INC Registration Statement on Form S-1 Filed April 24, 2024 File No. |
|
| May 1, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 1, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorporation) (Commission |
|
| May 1, 2024 |
APDN / Applied DNA Sciences, Inc. / Leviticus Partners LP Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. )* Applied DNA Sciences, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 03815U409 - (CUSIP Number) 04/25/2024 - (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this schedule i |
|
| May 1, 2024 |
Cell - Free Enzymatic DNA Empowering the Genetic Medicines Revolution Nasdaq: APDN Exhibit 99.1 Cell - Free Enzymatic DNA Empowering the Genetic Medicines Revolution Nasdaq: APDN The statements made by Applied DNA in this presentation may be “forward - looking” in nature within the meaning of Section 27 A of the Securities Act of 1933 , Section 21 E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995 . Forward - looking statements desc |
|
| April 24, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Applied DNA Sciences, Inc. |
|
| April 24, 2024 |
As filed with the Securities and Exchange Commission on April 23, 2024 As filed with the Securities and Exchange Commission on April 23, 2024 Registration No. |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 22, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorp |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 22, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorporation) (Commissi |
|
| April 22, 2024 |
Form of Sixth Certificate of Amendment to the Certificate of Incorporation Exhibit 3.1 PROPOSED FORM OF SIXTH CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF APPLIED DNA SCIENCES, INC. Applied DNA Sciences, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY THAT: FIRST: Article IV of the Certificate of Incorporation, as amended (the “Certificate of Incorporation”), |
|
| April 22, 2024 |
Applied DNA Announces 1-For-20 Reverse Stock Split Exhibit 99.1 Applied DNA Announces 1-For-20 Reverse Stock Split STONY BROOK, N.Y. – April 22, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-20 stock split of its common stock, to be effective as of 12:01 a.m. Eastern Time on Thursday, April 25, 2024. Applied DNA common stock will be |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 16, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorporation) (Commissi |
|
| April 19, 2024 |
Form of Purchase Warrant Amendment Exhibit 10.1 AMENDMENT TO COMMON STOCK PURCHASE WARRANT THIS AMENDMENT TO COMMON STOCK PURCHASE WARRANT (this “Amendment”), dated as of April 16, 2024, is by and between Applied DNA Sciences, Inc., a Delaware corporation (the "Company"), and [●] (the “Holder”). WHEREAS, pursuant to a Placement Agency Agreement, dated January 31, 2024, by and among the Company and Maxim Group, LLC and Securities Pu |
|
| April 19, 2024 |
Form of Book-Entry Warrant Amendment Exhibit 10.2 AMENDMENT TO WARRANT AGREEMENT THIS AMENDMENT TO WARRANT AGREEMENT (this “Amendment”), dated as of April 16, 2024, is by and between Applied DNA Sciences, Inc., a Delaware corporation (the "Company"), and Equiniti Trust Company, LLC, a New York limited liability trust company (formerly known as American Stock Transfer & Trust Company, LLC), as Warrant Agent (the “Warrant Agent”). WHER |
|
| April 16, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 15, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorporation) (Commissi |
|
| March 20, 2024 |
Up to 11,288,122 shares of Common Stock underlying the Common Warrants Applied DNA Sciences, Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-277832 PROSPECTUS Up to 11,288,122 shares of Common Stock underlying the Common Warrants Applied DNA Sciences, Inc. This prospectus relates to the resale from time to time, by the selling stockholders (the “Selling Stockholders”) identified in this prospectus under the caption “Selling Stockholders,” of up to 11,288,122 shares of common stock, |
|
| March 18, 2024 |
United States securities and exchange commission logo March 18, 2024 James Hayward, Ph. |
|
| March 18, 2024 |
Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 March 18, 2024 Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 March 18, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-3720 Re: Applied DNA Sciences, Inc. Registration Statement on Form S-1 Filed March 12, 2024, as amended File No. 333-277832 Ladies and Gent |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 15, 2024 |
As filed with the Securities and Exchange Commission on March 15, 2024. As filed with the Securities and Exchange Commission on March 15, 2024. Registration Statement No. 333-277832 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Applied DNA Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 7380 59-2262718 (State or other jurisdictio |
|
| March 14, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 12, 2024 |
As filed with the Securities and Exchange Commission on March 11, 2024. As filed with the Securities and Exchange Commission on March 11, 2024. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Applied DNA Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 7380 59-2262718 (State or other jurisdiction of incorporation or org |
|
| March 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) APPLIED DNA SCIENCES, INC. |
|
| March 4, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| February 12, 2024 |
APDN / Applied DNA Sciences, Inc. / Grossman Bruce - SCHEDULE 13G Passive Investment SC 13G 1 eh24044723313g-adna.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied DNA Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03815U201 (CUSIP Number) February 2, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate b |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 |
|
| February 8, 2024 |
Lease Renewal Agreement dated January 10, 2024 (Laboratory Lease). Exhibit 10.3 December 18, 2023 Beth Jantzen, CPA Chief Financial Officer Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, NY 11790 Dear Ms. Jantzen, In accordance with your Lease dated February 24, 2023, the Long Island High Technology Incubator, Inc. hereby renews your lease for a period of one year. The Term of the renewal is 2/1/2024 to 1/31/2025. Applied DNA Sciences, Inc. occu |
|
| February 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorporation) (Commis |
|
| February 8, 2024 |
Exhibit 99.1 Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results - Company On Track to Initiate First-Phase GMP Production Capacity for mRNA Critical Starting Materials During First Half of Calendar 2024, Projects Initial Facility Capacity to Enable up to $15 Million1 of Linea IVT Revenue2 Annually - - Conference Call/Webcast Scheduled for Today at 4:30 PM ET - STONY BROOK, N.Y. |
|
| February 1, 2024 |
Exhibit 99.1 Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules STONY BROOK, N.Y., - January 31, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that it has entered into securities purchase agreements (SPAs) with certain existing institutional investors (collectively the “Hol |
|
| February 1, 2024 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT January 31, 2024 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”),Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $3,437,233.15 of registered and unregistered securities of the Company, including, b |
|
| February 1, 2024 |
Exhibit 4.1 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| February 1, 2024 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 31, 2024, between Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| February 1, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-272267 PROSPECTUS SUPPLEMENT (To prospectus dated June 6, 2023) APPLIED DNA SCIENCES, INC. 3,228,056 Shares of Common Stock Pre-Funded Warrants to Purchase 2,416,005 Shares of Common Stock We are offering 3,228,056 shares of our common stock (the "Shares") at a price of $0.609 per share, to investors pursuant to this prospectus supplement and t |
|
| February 1, 2024 |
Form of Private Common Warrant. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 30, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36745 APPLIED DN |
|
| January 10, 2024 |
SC 13G/A 1 Applieddna13g123123t.txt APPLIED DNA 13G/A THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Applied DNA Sciences, Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 03815U300 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this S |
|
| January 8, 2024 |
A Next Generation Platform for Genetic Medicine Manufacturing Nasdaq: APDN Exhibit 99.1 A Next Generation Platform for Genetic Medicine Manufacturing Nasdaq: APDN The statements made by Applied DNA in this presentation may be “forward - looking” in nature within the meaning of Section 27 A of the Securities Act of 1933 , Section 21 E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995 . Forward - looking statements describe App |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Nu |
|
| January 5, 2024 |
Exhibit 10.1 January 3, 2024 ViA EMAIL [email protected] James A. Hayward, Ph.D., Sc.D. President and Chief Executive Officer Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, NY 11790 Re: Voluntary Base Salary Reduction Dear Jim: As you are aware, Applied DNA Sciences, Inc. (the “Company”) is experiencing certain cash flow difficulties. Accordingly, in order to assist the Com |
|
| January 5, 2024 |
Exhibit 10.2 January 3, 2024 ViA EMAIL [email protected] Ms. Judy Murrah Chief Operating Officer Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, NY 11790 Re: Voluntary Base Salary Reduction Dear Judy: As you are aware, Applied DNA Sciences, Inc. (the “Company”) is experiencing certain cash flow difficulties. Accordingly, in order to assist the Company with this current situati |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 4, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Nu |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36745 APPLIED DN |
|
| December 7, 2023 |
Exhibit 99.1 Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results - Conference Call/Webcast Scheduled for Today at 4:30 PM ET - STONY BROOK, N.Y. - December 7, 2023 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for its fourth quarter ended September 30, 2023. “O |
|
| December 7, 2023 |
Subsidiaries of Applied DNA Sciences, Inc. Exhibit 21.1 SUBSIDIARIES OF APPLIED DNA SCIENCES, INC. Subsidiary State or Country of Incorporation APDN (B.V.I.) Inc. British Virgin Islands Applied DNA Sciences Europe Limited United Kingdom Applied DNA Sciences India Private Limited India LineaRX, Inc. Delaware Applied DNA Clinical Labs LLC Delaware Spindle Biotech, Inc. Canada |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2023 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| December 6, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 1, 2023 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| November 7, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2023 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
